Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13346690 | 0.98 | KDM4E (0.36) | KDM4EALDH1A1TSHREPHX2TDP1 | |
| SCHEMBL13346691 | 0.98 | KDM4E (0.36) | KDM4EALDH1A1TSHREPHX2TDP1 | |
| SCHEMBL13346688 | 0.98 | KDM4E (0.36) | KDM4EALDH1A1TSHREPHX2TDP1 | |
| SCHEMBL13346692 | 0.98 | KDM4E (0.36) | KDM4EALDH1A1TSHREPHX2TDP1 | |
| SCHEMBL13346689 | 0.98 | KDM4E (0.36) | KDM4EALDH1A1TSHREPHX2TDP1 | |
| SCHEMBL3682572 | 0.95 | KDM4E (0.38) | KDM4EALDH1A1TSHREPHX2TDP1 | |
| SCHEMBL3677071 | 0.87 | KDM4E (0.40) | KDM4EALDH1A1TSHREPHX2TDP1 | |
| SCHEMBL1975023 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1TSHREPHX2TDP1 | |
| SCHEMBL4445579 | 0.82 | KDM4E (0.44) | KDM4EALDH1A1TSHREPHX2TDP1 | |
| SCHEMBL30996063 | 0.82 | KDM4E (0.44) | KDM4EALDH1A1TSHREPHX2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149826-B1 | Ester compounds having alicyclic structure, and methods for preparing the same | SHINETSU CHEMICAL CO (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-7714087-B2 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20090137757-A1 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | IMUTA JUNICHI | 2009-05-28 | — | — | US | disclosed |
| US-7393907-B2 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2008-07-01 | — | — | US | disclosed |
| US-6403823-B2 | Ester compounds having alicyclic structure and method for preparing same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-6403822-B2 | NUCLEOPHILIC ADDITION OF ALICYCLIC CARBONYL AND METAL ENOLATE OF ACETATE; POLYCARBON MONOMERS FOR PHOTORESISTS; HIGH REACTIVITY AND SUBSTRATE AFFINITY | SHIN-ETSU CHEMICAL, CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20010051741-A1 | Novel ester compounds having alicyclic structure and method for preparing same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| US-20010051742-A1 | Novel ester compounds having alicyclic structure and method for preparing same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-1149826-A2 | Ester compounds having alicyclic structure, and methods for preparing the same | Shin-Etsu Chemical Co., Ltd. (JP) | 2001-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051742-A1 | Novel ester compounds having alicyclic structure and method for preparing same | ARCN1, ECH1, GAR1 | KDM4E 876/4885ALDH1A1 460/4885TSHR 4361/4885 |
| US-20010051741-A1 | Novel ester compounds having alicyclic structure and method for preparing same | ARCN1, ECH1, ASIC1 | KDM4E 795/4885ALDH1A1 421/4885TSHR 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.